Form 8-K - Groowe Newsroom

8-K — Alpha Cognition Inc.

Accession: 0001213900-26-034778

Filed: 2026-03-26

Period: 2026-03-25

CIK: 0001655923

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — ea0283622-8k_alpha.htm (Primary)

EX-99.1 — PRESS RELEASE ANNOUNCES FINANCIAL RESULTS FOR THE 2025 FISCAL YEAR DATED MARCH 26, 2026 (ea028362201ex99-1.htm)

GRAPHIC (ea028362201_ex99-1img1.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0283622-8k_alpha.htm · Sequence: 1

false

0001655923

00-0000000

0001655923

2026-03-25

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

Current

Report

Pursuant

to Section 13 or 15(d) of the

Securities

Exchange Act of 1934

Date

of Report (Date of earliest event reported): March 25, 2026

Alpha

Cognition Inc.

(Exact

name of registrant as specified in its charter)

British

Columbia

001-42403

N/A

(State

or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S.

Employer

Identification Number)

1452

Hughes Rd., Ste 200

Grapevine, Texas

76051

(Address

of principal executive offices)

(Zip

Code)

Registrant’s

telephone number, including area code: 858-344-4375

Not

Applicable

(Former

name or former address, if changed since last report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class:

Trading

Symbol

Name

of each exchange on which registered:

Common

Shares, no par value

ACOG

The

Nasdaq Stock Market LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act (§230.405 of this

chapter) or Rule 12b-2 of the Exchange Act (§240.12b-2 of this chapter).

Emerging

growth company ☒

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

2.02 Results

of Operation and Financial Condition

March 26, 2026, the Company issued a press release announcing its financial and operational results for the year ended December 31, 2025

and announcing a management call to discuss the financial results (the “Press Release”). A copy of the Press Release

is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

accordance with General Instruction B.2 of Form 8-K, the information in this Form 8-K (including Exhibit 99.1) is being “furnished,”

and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange

Act”), or otherwise subject to the liabilities of that Section nor shall they be deemed incorporated by reference in any filing

made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference

in such a filing.

Item

9.01

Financial

Statements and Exhibits.

(d)

Exhibits.

Exhibit

No.

Description

99.1*

Press Release announces financial results for the 2025 fiscal year dated March 26, 2026

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document)

* The

Exhibit relating to Item 2.02 is intended to be furnished to, not filed with, the SEC pursuant to Regulation FD.

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

ALPHA

COGNITION INC.

By:

/s/

Michael McFadden

Michael

McFadden

Chief

Executive Officer

Dated:

March 26, 2026

EX-99.1 — PRESS RELEASE ANNOUNCES FINANCIAL RESULTS FOR THE 2025 FISCAL YEAR DATED MARCH 26, 2026

EX-99.1

Filename: ea028362201ex99-1.htm · Sequence: 2

Exhibit

99.1

Alpha

Cognition Inc.

Nasdaq:

ACOG

1452

Hughes Road, Ste. 200

Grapevine, TX 65051

www.alphacognition.com

info@alphacognition.com

Alpha

Cognition Inc. Reports Fiscal 2025 Financial Results and Provides Operational Update

Alpha

Cognition generated fourth quarter 2025 ZUNVEYL net product revenue of $2.5 million, contributing to full year 2025 total revenue of

$10.2 million

Fourth

quarter bottles dispensed increased 62% quarter-over-quarter to 4,941, with December representing the strongest month since launch

Executed

second national PBM contract and initiating three studies to further support ZUNVEYL’s positioning in long-term care Alzheimer’s

patients

Cash

and cash equivalents totaled $66 million at year-end 2025, supporting the company’s continued target of operating profitability

in 2027

Company

to host conference call and webcast today, March 26, at 4:30 p.m. ET

VANCOUVER,

B.C., Grapevine, TX, March 26, 2026. Alpha Cognition Inc. (ACOG: NASDAQ) (“Alpha Cognition”, “ACI”,

or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders,

today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.

“2025

was a year of strong commercial execution for Alpha Cognition as we continued to build momentum for ZUNVEYL – the first new oral

Alzheimer’s treatment approved in more than 15 years. In the fourth quarter, we saw strong growth in demand, with December representing

our strongest month since launch. We’re encouraged by the increasing rates of repeat ordering, indicating ZUNVEYL is moving beyond

initial trial and becoming increasingly integrated into routine management in long-term care,” said Michael McFadden, Chief Executive

Officer of Alpha Cognition.

“Importantly,

we also executed a second national PBM contract, bringing us to two of the four major PBMs relevant to long-term care. Combined with

the consistent clinical feedback we’re hearing on ZUNVEYL’s tolerability and behavioral profile, we believe we are well positioned

to continue driving adoption as payer pull-through improves in 2026. We enter the year well-capitalized and focused on expanding our

commercial footprint, deepening prescriber engagement, and advancing toward operational profitability in 2027.”

ZUNVEYL

Commercial Performance

● Net

ZUNVEYL Revenue: Generated approximately $2.5 million in net product revenue in the fourth

quarter of 2025. Launch-to-date net product revenue through year-end 2025 was approximately

$6.8 million. Total revenues for the year 2025 were approximately $10.2 million, inclusive

of net product revenues and licensing revenue.

● Bottles

Dispensed: Dispensed 4,941 bottles in Q4, representing 62% quarter-over-quarter

growth. December was the strongest single sales month since launch selling 1,859 bottles.

● Expanding

Prescriber Base and Adoption Expansion: Q4 prescribers increased 50% over the prior

quarter. Cumulative homes with prescriptions increased 26% in Q4, an early indicator of broadening

adoption in the long-term care setting.

● Commercial

Reach: Sales team reached 1,986 homes in the quarter and have engaged with approximately

4,000 unique facilities since commercial launch.

● Payer

progress: Executed a second national PBM agreement during the quarter and now has agreements

with two of the four major PBMs relevant to the long-term care market.

Alpha

Cognition Inc.

Nasdaq:

ACOG

1452

Hughes Road, Ste. 200

Grapevine, TX 65051

www.alphacognition.com

info@alphacognition.com

Recent

and Upcoming Business, Clinical, and Operational Highlights

● Alpha

Cognition will present new clinical data on ZUNVEYL at the upcoming American Association

of Geriatric Psychiatrists (AAGP), and the Neuroscience Education Institute (NEI) Spring

Congress in Q2 2026.

● Alpha

Cognition continues to expect two product approvals ex-US via our partner, CMS, in Asia.

● Announced

Issuance of additional U.S. patent covering ZUNVEYL dosing regimens.

● Enrollment

is ongoing in the BEACON study, a real-world effectiveness study to evaluate the impact of

ZUNVEYL on cognition, behavior, and tolerability in the long-term care setting.

● Plan

to initiate CONVERGE study, a retrospective data analysis in the long-term care environment

that will provide data on ZUNVEYL in long term care Alzheimer’s patients. The analysis

will provide data from approximately 400 patients for ZUNVEYL in areas of tolerability, dosing,

and polypharmacy.

● Plan

to Initiate RESOLVE study, a phase 4 study in Alzheimer’s disease (“AD”)

patients to assess ZUNVEYL effect on tolerability and behaviors associated with AD. The Company

believes the data could be supportive of future regulatory discussions and will be utilized

with physicians and payers to inform them on tolerability of ZUNVEYL

● Alpha

Cognition plans to complete its preclinical work with a sublingual formulation and advance

the product to the clinic in 2026 for treatment of mild-to-moderate AD. The Company believes

this product, if approved, would be a disruptive formulation for AD patients with dysphagia

or aphagia who currently have limited options for medication treatment

Full

Year Fiscal 2025 Financial Results

● Revenues:

ZUNVEYL net product revenues were $6.8 million, and licensing revenue totaled $3.4 million,

for a combined total of $10.2 million for the year ended December 31, 2025.

● Research

& Development: Expenses were $1.9 million, compared to $3.9 million for fiscal year

2024 as the Company transitioned to commercial stage.

● Selling,

General & Administrative: Expenses were $29.1 million, up from $8.0 million in 2024,

reflecting increased commercial investment in personnel and infrastructure.

● Operating

Loss: $22.7 million, compared to $12.0 million in 2024.

● Net

Loss: $20.7 million, compared to $14.8 million in 2024. The Company benefited from favorable

changes to the fair value warrant liabilities.

● Cash

Position: $66.0 million as of December 31, 2025, compared to $48.5 million as of December

31, 2024. Following the $40 million in net proceeds from our capital raise completed in October

2025, the Company expects a cash runway of approximately two years at forecasted operating

levels.

Alpha

Cognition Inc.

Nasdaq:

ACOG

1452

Hughes Road, Ste. 200

Grapevine, TX 65051

www.alphacognition.com

info@alphacognition.com

Conference

Call Information

Alpha

Cognition will host a conference call and webcast today, March 26 at 4:30 p.m. Eastern Time. To access the live conference call by phone,

dial 877-407-9039 or 201-689-8470. The live audio webcast will be accessible at https://viavid.webcasts.com/starthere.jsp?ei=1753776&tp_key=c7346c57d0.

An archived version of the webcast will be available for replay on the Alpha Cognition Investor Relations page following the event.

About

Alpha Cognition Inc.

Alpha

Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative

diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which

there are currently no approved treatment options.

ZUNVEYL

is a patented drug approved as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected

minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it

binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062

is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation

for Cognitive Impairment with mTBI.

For

further information:

Investor

Relations

LifeSci

Advisors, PJ Kelleher

pkelleher@lifesciadvisors.com

INDICATION

AND USAGE

ZUNVEYL

is a cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults.

IMPORTANT

SAFETY INFORMATION

CONTRAINDICATIONS

ZUNVEYL

is contraindicated in patients with known hypersensitivity to benzgalantamine, galantamine, or to any inactive ingredients in ZUNVEYL.

Serious skin reactions have occurred.

WARNINGS

AND PRECAUTIONS

Serious

Skin Reactions: Serious skin reactions (Stevens-Johnson syndrome and acute generalized exanthematous pustulosis) have been reported

in patients receiving galantamine (the active metabolite of ZUNVEYL tablets). If signs or symptoms suggest a serious skin reaction, use

of this drug should not be resumed, and alternative therapy should be considered.

Alpha

Cognition Inc.

Nasdaq:

ACOG

1452

Hughes Road, Ste. 200

Grapevine, TX 65051

www.alphacognition.com

info@alphacognition.com

Anesthesia:

See Drug Interactions Section

Cardiovascular

Conditions: Cholinesterase inhibitors, including ZUNVEYL, have vagotonic effects on the sinoatrial and atrioventricular nodes, leading

to bradycardia and AV block. Bradycardia and all types of heart block have been reported in patients taking cholinesterase inhibitors,

both with and without known underlying cardiac conduction abnormalities. Therefore, all patients should be considered at risk for adverse

effects on cardiac conduction.

Patients

treated with galantamine up to 24 mg/day using the recommended dosing schedule showed a dose-related increase in risk of syncope.

Gastrointestinal

Conditions: Cholinesterase inhibitors, including ZUNVEYL, may increase gastric acid secretion. Patients should be monitored closely

for active or occult gastrointestinal bleeding, especially those with a history of ulcer disease or those receiving concurrent nonsteroidal

anti-inflammatory drugs (NSAIDs). Clinical studies of galantamine have shown no increase, relative to placebo, in the incidence of either

peptic ulcer disease or gastrointestinal bleeding.

Galantamine

has been shown to produce nausea, vomiting, diarrhea, anorexia, and weight loss. Monitor the patient’s weight during therapy with

ZUNVEYL

Genitourinary

Conditions: Although this was not observed in clinical trials with galantamine, cholinesterase inhibitors, including ZUNVEYL, may

cause bladder outflow obstruction.

Neurological

Conditions: Cholinesterase inhibitors are believed to have some potential to cause generalized convulsions. Seizure activity may

also be a manifestation of Alzheimer’s disease. Patients with Alzheimer’s disease should be monitored closely for seizures

while taking ZUNVEYL.

Pulmonary

Conditions: Cholinesterase inhibitors, including ZUNVEYL, should be prescribed with care to patients with a history of severe asthma

or obstructive pulmonary disease. Monitor for respiratory adverse reactions.

ADVERSE

REACTIONS

The

most common adverse reactions with galantamine tablets (≥5%) were nausea, vomiting, diarrhea, dizziness, headache, and decreased appetite.

DRUG

INTERACTIONS

Use

with Anticholinergics: Galantamine has the potential to interfere with the activity of anticholinergic medications.

Use

with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect is expected when cholinesterase inhibitors are given

concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents or cholinergic agonists such

as bethanechol.

USE

IN SPECIFIC POPULATIONS

Pregnancy:

Based on animal data may cause fetal harm.

Hepatic

Impairment: In patients with moderate hepatic impairment, a decrease in clearance of galantamine was observed; therefore, a dosage

adjustment is recommended. Use of ZUNVEYL in patients with severe hepatic impairment is not recommended.

Renal

Impairment: In patients with a creatinine clearance of 9 to 59 mL/min, an increase in exposure of galantamine was observed; therefore,

a dosage adjustment is recommended. Use of ZUNVEYL in patients with creatinine clearance less than 9 mL/min is not recommended.

These

are not all of the possible side effects of ZUNVEYL. You can report side effects to the FDA. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.

Please click here for Full Prescribing Information.

Alpha

Cognition Inc.

Nasdaq:

ACOG

1452

Hughes Road, Ste. 200

Grapevine, TX 65051

www.alphacognition.com

info@alphacognition.com

Forward-looking

Statements

This

news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical

fact, any information contained in this news release may be a forward-looking statement that reflects the Company’s current views

about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual

results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these

forward-looking statements. Such statements include but are not limited to statements regarding the future success of the commercialization

of ZUNVEYL, statement regarding the timing and potential outcomes of the Company’s ongoing clinical and preclinical studies, statements

regarding future presentations, statements regarding potential product approvals and other statements regarding the future anticipated

operations of the Company. In some cases, you can identify forward-looking statements by the words “may,” “might,”

“will,” “could,” “would,” “should,” “expect,” “intend,” “plan,”

“objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,”

“potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,”

or the negative of these terms, or other comparable terminology intended to identify statements about the future. Although the Company

believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination

of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot ensure

that the actual results will be consistent with these forward-looking statements. These forward-looking statements are subject to certain

risks, including risks regarding our ability to raise sufficient capital to implement our plans to continue to commercialize ZUNVEYL,

risks regarding the efficacy and tolerability of ZUNVEYL, risks related to ongoing regulatory oversight on the safety of ZUNVEYL, risk

related to market adoption of ZUNVEYL, risks related to the Company’s intellectual property in relation to ZUNVEYL, risks related

to the commercial manufacturing, distribution, marketing and sale of ZUNVEYL, risks related to product liability, risks related to our

ongoing clinical trials and other risks as described in the Company’s filings with Canadian securities regulatory authorities and

available at www.sedar.com and the Company’s filings with the United States Securities and Exchange Commission (the “SEC”),

including those risk factors under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K

filed with the SEC on March 31, 2025 and the Company’s other filings with the SEC available at www.sec.gov. These forward-looking

statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward-looking

statements for any reason, even if new information becomes available in the future, except as required by law.

Note

regarding Key Performance Indicators

the company began commercial sales of ZUNVEYL in 2025, management has identified several key performance indicators that it utilizes

to assess the progress of commercialization and sale of ZUNVEYL and the success of its operations period over period. These key performance

indicators include bottles dispensed, number of prescribers, homes and unique facilities engaged. These indicators are defined below

along with management’s reasons for focusing on these indicators.

“Bottles

dispensed” refers to the number of 30-day prescriptions of ZUNVEYL filled during a given period. This data is sourced from third-party

providers. Reported figures reflect the bottles recorded as dispensed within that period based on management’s review of the data.

Because the data may be updated over time, actual totals may vary slightly.

Alpha

Cognition Inc.

Nasdaq:

ACOG

1452

Hughes Road, Ste. 200

Grapevine, TX 65051

www.alphacognition.com

info@alphacognition.com

Management

considers bottles dispensed a key performance metric because it closely reflects real-world product usage and is a meaningful indicator

of ZUNVEYL’s commercial performance and the Company’s operational progress.

“Prescribers”

refers to the number of healthcare providers actively writing prescriptions for ZUNVEYL at the end of a reported period. This data is

sourced from third-party providers and is evaluated on a weekly basis. The reported number reflects prescriber activity at a specific

point in time and may not represent the total number of prescribers throughout the entire period.

Management

considers prescribers a key metric because it indicates the level of commercial adoption of ZUNVEYL among healthcare providers and helps

assess the potential for future growth in bottles dispensed.

“Homes”

refers to the number of long-term care facilities where medical staff have prescribed ZUNVEYL to patients residing in those facilities.

“Unique facilities engaged” refers to the number of long-term care facilities with which the Company’s sales team has

had discussions regarding prescribing ZUNVEYL.

This

data is sourced from third-party providers. Reported figures may vary from actual totals as data is updated over time.

Management

considers homes and unique facilities engaged to be key performance metrics, as they reflect the effectiveness of the Company’s

sales efforts in reaching potential prescribers and expanding coverage within the long-term care market.

Note

regarding Financial Statements

The

Company’s actual consolidated financial results remain subject to completion of our annual audit procedures for the year ended

December 31, 2025. Our actual audited consolidated financial results for the year ended December 31, 2025 are expected to be reported

in connection with the filing of our Annual Report on Form 10-K for the year ended December 31, 2025, which is expected to be filed on

or about March 31, 2026. Our actual consolidated financial results may differ from the results included in this release, including as

a result of audit adjustments and other developments that may arise between now and when the Form 10-K is finalized and filed. This release

should not be viewed as a substitute for audited consolidated financial statements and related notes as of and for the year ended December

31, 2025 prepared in accordance with Generally Accepted Accounting Principles (“GAAP”). Accordingly, you should not place

undue reliance on this release, which has been prepared by, and is the responsibility of, our management.

Alpha

Cognition Inc.

Nasdaq:

ACOG

1452

Hughes Road, Ste. 200

Grapevine, TX 65051

www.alphacognition.com

info@alphacognition.com

Alpha

Cognition Inc.

Consolidated

Balance Sheets

(Unaudited)

December 31,

2025

2024

ASSETS

Current

assets

Cash

and cash equivalents

$ 66,046,789

$ 48,546,210

Restricted

cash

58,400

17,872

Accounts

receivable, net

4,236,136

Inventory

5,123,496

615,133

Prepaid

expenses and other current assets

3,545,451

1,071,963

Total

current assets

79,010,272

50,251,178

Other

assets

45,714

Equipment,

net

328,540

27,077

Intangible

assets, net

391,423

412,969

Total

assets

$ 79,730,235

$ 50,736,938

LIABILITIES

AND STOCKHOLDERS’ EQUITY

Current

liabilities

Accounts

payable and accrued liabilities

$ 8,976,904

$ 2,439,289

Current

portion of promissory note - related party

911,463

Current

deferred income

153,171

Total

current liabilities

9,130,075

3,350,752

Deferred

income

35,944

Option

liability

3,174,662

2,368,218

Warrant

liabilities

4,812,198

5,820,358

Other

long-term liabilities

47,181

102,783

Total

liabilities

17,200,060

11,642,111

Stockholders’

equity

Common shares, no

par value, unlimited shares authorized, 21,742,104 and 16,019,787 shares issued and outstanding as of December 31, 2025, and December

31, 2024

133,891,673

99,128,230

Class B preferred

shares, no par value, unlimited shares authorized, 316,655 shares issued and outstanding as of December 31, 2025, and December 31,

2024

Additional

paid-in capital

25,849,516

16,507,736

Accumulated

other comprehensive loss

(104,301 )

Accumulated

deficit

(97,106,775 )

(76,436,900 )

Total

stockholders’ equity

62,530,175

39,094,827

Total

liabilities and stockholders’ equity

$ 79,730,235

$ 50,736,938

Alpha

Cognition Inc.

Nasdaq:

ACOG

1452

Hughes Road, Ste. 200

Grapevine, TX 65051

www.alphacognition.com

info@alphacognition.com

Alpha

Cognition Inc.

Condensed

Consolidated Statement of Operations

(Unaudited)

For

the Year Ended

December 31,

2025

2024

Revenues

Product

sales, net

$ 6,792,024

$ 0

Licensing

3,428,251

Total revenues

10,220,275

Cost of product sales,

excluding amortization of intangible asset

474,006

Cost of licensing revenue

1,441,317

Amortization of intangible

asset

21,546

79,875

Research and development

1,867,972

3,920,412

Selling,

general and administrative expenses

29,076,123

8,012,230

Total

operating expenses

32,880,964

12,012,517

Loss

from operations

(22,660,689 )

(12,012,517 )

Other

income (expenses)

1,990,814

(2,776,210 )

Net

loss

$ (20,669,875 )

$ (14,788,727 )

Net loss per share, basic

$ (1.17 )

$ (2.04 )

Weighted-average

shares used to compute net loss per share, basic

17,680,597

7,247,864

GRAPHIC

Filename: ea028362201_ex99-1img1.jpg · Sequence: 3

Binary file (3741 bytes)

Download ea028362201_ex99-1img1.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Mar. 25, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Mar. 25, 2026

Entity File Number

001-42403

Entity Registrant Name

Alpha

Cognition Inc.

Entity Central Index Key

0001655923

Entity Tax Identification Number

00-0000000

Entity Incorporation, State or Country Code

Entity Address, Address Line One

1452

Hughes Rd.

Entity Address, Address Line Two

Ste 200

Entity Address, City or Town

Grapevine

Entity Address, State or Province

Entity Address, Postal Zip Code

76051

City Area Code

858

Local Phone Number

344-4375

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Shares, no par value

Trading Symbol

ACOG

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration